Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
OLB vs KTTA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
KTTA Captures Overall Composite Edge (42.1 HOLD vs 48.6 HOLD), While OLB Leads 3–2 on Growth & Valuation Pillars
KTTA Overall Winner
6-Pillar Tally: OLB 3 – 2 KTTA (1 Tie)
Matrix Metrics: OLB 3 – 5 KTTA
As of Nov 20, 2026, Pasithea Therapeutics Corp. (KTTA) captures the overall head-to-head institutional edge over The OLB Group, Inc. (OLB) on higher Unified Composite conviction (42.1/100 HOLD vs. 48.6/100 HOLD) after splitting the core matrix 5–3 (led by Growth & Scale, Profitability & Quality), while OLB wins 3–2 across the 6-pillar growth and valuation breakdown. OLB trades at $0.12 (N/M Forward P/E, -73.3% operating margin) versus KTTA at $0.48 (N/M Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While OLB currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. KTTA 42.1/100 HOLD), KTTA captures the overall institutional head-to-head verdict (5–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -73.3% operating margin) and revenue trajectory (+1498.1% vs. -43.6% YoY).
- Technical & Structure Timing Caution: OLB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.6); meanwhile KTTA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About OLB vs KTTA
OLB
The OLB Group, Inc. Common Stock
$0.12
-4.33% 1D
Market Cap
$3.8M
TTM Revenue
$7.0M
Forward P/E
N/M
Beta / 30D Vol
1.80β · 120% Vol
Unified Composite Score
48.6
HOLD
Tech 48.0
Fund 46.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
KTTA
Head-to-Head Winner
Pasithea Therapeutics Corp. Common Stock
$0.48
-0.48% 1D
Market Cap
$17.7M
TTM Revenue
$486,559
Forward P/E
N/M
Beta / 30D Vol
0.68β · 185% Vol
Unified Composite Score
42.1
HOLD
Tech 20.0
Fund 40.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Distribution · Trim / tighten stop
6-Pillar Scorecard Institutional Category Breakdown (OLB 3 – 2 KTTA)
1. Valuation Multiples
OLB
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
0.4x
36.3x
2. Growth & Scale
KTTA
Revenue Growth (YoY)
-43.6%
+1498.1%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$7.0M
$486,559
Market Cap
$3.8M
$17.7M
3. Profitability & Quality
KTTA
Gross Margin
-30.9%
-0.5%
Operating Margin
-73.3%
0.0%
Net Profit Margin
-68.2%
0.0%
Return on Equity (ROE)
-70.8%
-88.8%
4. Balance Sheet & Cash Flow
OLB
Cash Generation (TTM)
-$2.6M
-$18M
Cash Flow Margin
-36.3%
N/A
Net Cash / Leverage
$1.1M Net Cash
$1.31 Book/Sh · -88.8% ROE
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Distribution
6. R&D & Supply-Chain Moat
OLB
OpEx & R&D Intensity
42.4% of Rev ($3.0M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Software - Infrastructure Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: OLB (3) vs KTTA (5)| Institutional Metric | OLB | KTTA | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $3.8M | $17.7M | KTTA | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | -43.6% | +1498.1% | KTTA | |
| Operating Margin (TTM) | -73.3% | 0.0% | KTTA | |
| Net Profit Margin | -68.2% | 0.0% | KTTA | |
| Return on Equity (ROE) | -70.8% | -88.8% | OLB | |
| 52-Week Range Position | 0% ($0–$2) | 11% ($0–$2) | KTTA | |
| Beta / 30D Volatility | 1.80β · 120% Vol | 0.68β · 185% Vol | OLB | |
| Unified Institutional Score | 48.6 / 100 (HOLD) | 42.1 / 100 (HOLD) | OLB | |
| Trailing 12M Revenue (USD) | $7.0M | $486,559 | Scale | |
| Gross Profit Margin (TTM) | -30.9% | -0.5% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.4x EV/Rev | N/M PEG · 36.3x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$2.6M ($1.1M Net Cash) | -$18M ($1.31 Book/Sh · -88.8% ROE) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
KTTA +70.78 pp
3M Horizon
KTTA +56.13 pp
6M Horizon
KTTA +43.84 pp
1Y Horizon
KTTA +87.95 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OLB Revenue | KTTA Revenue | OLB Op. Margin | KTTA Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $10M | N/A | 5.9% | N/A | OLB |
| FY2019 | $10M | N/A | -2.6% | N/A | OLB |
| FY2020 | $10M | N/A | -7.5% | N/A | OLB |
| FY2021 | $20M | $0M | -28.5% | -29925.7% | OLB |
| FY2022 | $30M | $0M | -26.9% | -2587.3% | OLB |
| FY2023 | $30M | N/A | -76.8% | N/A | OLB |
| FY2024 | $10M | N/A | -90.9% | N/A | OLB |
| FY2025 | $10M | N/A | -59.5% | N/A | OLB |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
OLB
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact OLB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
KTTA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact KTTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
OLB Moat Profile
Cyclical / Execution-Driven Positioning
Software - Infrastructure Operator
OpEx & R&D Reinvestment
42.4% of Rev ($3.0M)
90D Engineering Disclosures
0 Published
KTTA Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ OLB vs KTTA Key Questions & Quantitative Answers
As of Nov 20, 2026, Pasithea Therapeutics Corp. (KTTA) captures the overall head-to-head institutional edge over The OLB Group, Inc. (OLB) on higher Unified Composite conviction (42.1/100 HOLD vs. 48.6/100 HOLD) after splitting the core matrix 5–3 (led by Growth & Scale, Profitability & Quality), while OLB wins 3–2 across the 6-pillar growth and valuation breakdown. OLB trades at $0.12 (N/M Forward P/E, -73.3% operating margin) versus KTTA at $0.48 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While OLB currently prints a higher short-term Unified Composite Score (48.6/100 HOLD vs. KTTA 42.1/100 HOLD), KTTA captures the overall institutional head-to-head verdict (5–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -73.3% operating margin) and revenue trajectory (+1498.1% vs. -43.6% YoY). Technical & Structure Timing Caution: OLB is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.6); meanwhile KTTA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
KTTA leads the Growth & Scale pillar: OLB posts -43.6% YoY revenue growth and +0.0% YoY earnings growth on $7.0M TTM revenue (-30.9% gross margin, -73.3% operating margin), compared with KTTA at +1498.1% YoY revenue growth and +0.0% YoY earnings growth on $486,559 TTM revenue (-0.5% gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), OLB cumulative revenue shifted +0.0% while KTTA shifted N/A. In operating R&D and SG&A reinvestment, OLB deploys 42.4% of Rev ($3.0M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for KTTA.
OLB screens cheaper on headline valuation multiples. OLB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.4x EV/Revenue (-36.3% FCF margin), whereas KTTA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 36.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OLB (-70.8% ROE) versus KTTA (-88.8% ROE) capital efficiency.
In options market volatility and institutional positioning, OLB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.80β · 120% Vol realized risk). By comparison, KTTA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 185% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
KTTA vs OLB · Reverse Pair
KTTA vs QNRX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal